259 related articles for article (PubMed ID: 6292254)
1. Calcium potentiates the cyclic nucleotide and phosphaturic response to parathyroid hormone infusion.
Bikle DD; Herman RH
J Clin Endocrinol Metab; 1983 Jan; 56(1):11-7. PubMed ID: 6292254
[TBL] [Abstract][Full Text] [Related]
2. Rapid development of renal resistance to low doses of synthetic bovine parathyroid hormone fragment 1-34. Dissociation of urinary cyclic adenosine monophosphate, phosphaturic, and calciuric responses.
Law WM; Heath H
J Clin Invest; 1983 Sep; 72(3):1106-13. PubMed ID: 6309905
[TBL] [Abstract][Full Text] [Related]
3. Parathyroid hormone does not increase nephrogenous cyclic AMP excretion by the dog.
Fox J; Heath H
Endocrinology; 1980 Dec; 107(6):2124-5. PubMed ID: 6253291
[TBL] [Abstract][Full Text] [Related]
4. Synthetic human parathyroid hormone-(1-34) for the study of pseudohypoparathyroidism.
Mallette LE; Kirkland JL; Gagel RF; Law WM; Heath H
J Clin Endocrinol Metab; 1988 Nov; 67(5):964-72. PubMed ID: 2846629
[TBL] [Abstract][Full Text] [Related]
5. Assessment of adenosine 3',5'-monophosphate excretion and an oral calcium tolerance test in the diagnosis of mild primary hyperparathyroidism.
Madvig P; Young G; Marcus R
J Clin Endocrinol Metab; 1984 Mar; 58(3):480-7. PubMed ID: 6319454
[TBL] [Abstract][Full Text] [Related]
6. [The diagnostic value of the determination of cyclic 3',5'-adenosine monophosphate (cAMP) in urine].
Gennari C; Galli M; Montagnani M; D'Amore I
Quad Sclavo Diagn; 1976 Mar; 12(1):15-38. PubMed ID: 190633
[TBL] [Abstract][Full Text] [Related]
7. Mechanism of resistance to the phosphaturic effect of the parathyroid hormone in the hamster.
Knox FG; Preiss J; Kim JK; Dousa TP
J Clin Invest; 1977 Apr; 59(4):675-83. PubMed ID: 14974
[TBL] [Abstract][Full Text] [Related]
8. Direct comparison of sustained infusion of human parathyroid hormone-related protein-(1-36) [hPTHrP-(1-36)] versus hPTH-(1-34) on serum calcium, plasma 1,25-dihydroxyvitamin D concentrations, and fractional calcium excretion in healthy human volunteers.
Horwitz MJ; Tedesco MB; Sereika SM; Hollis BW; Garcia-Ocaña A; Stewart AF
J Clin Endocrinol Metab; 2003 Apr; 88(4):1603-9. PubMed ID: 12679445
[TBL] [Abstract][Full Text] [Related]
9. Renal-resistant hormonoplethoric hypoparathyroidism with evidence for a defective response to cAMP.
Duck SC; Rosenberg EM; Ratzan SK; Haymond MW
J Clin Endocrinol Metab; 1978 Sep; 47(3):640-6. PubMed ID: 233678
[TBL] [Abstract][Full Text] [Related]
10. Renal adenylate cyclase and the interrelationship between parathyroid hormone and vitamin D in the regulation of urinary phosphate and adenosine cyclic 3',5'-monophosphate excretion.
Forte LR; Nickols GA; Anast CS
J Clin Invest; 1976 Mar; 57(3):559-68. PubMed ID: 175088
[TBL] [Abstract][Full Text] [Related]
11. Nephrogenous cyclic AMP levels in primary hyperparathyroidism.
Babka JC; Bower RH; Sode J
Arch Intern Med; 1976 Oct; 136(10):1140-4. PubMed ID: 184749
[TBL] [Abstract][Full Text] [Related]
12. Effects of the intravenous administration of calcium on nephrogenous cyclic AMP: use as a parathyroid suppression test.
Broadus AE; Deftos LJ; Bartter FC
J Clin Endocrinol Metab; 1978 Mar; 46(3):477-87. PubMed ID: 221521
[TBL] [Abstract][Full Text] [Related]
13. Urinary cyclic adenosine 3',5'-monophosphate response in McCune-Albright syndrome: clinical evidence for altered renal adenylate cyclase activity.
Zung A; Chalew SA; Schwindinger WF; Levine MA; Phillip M; Jara A; Counts DR; Kowarski AA
J Clin Endocrinol Metab; 1995 Dec; 80(12):3576-81. PubMed ID: 8530601
[TBL] [Abstract][Full Text] [Related]
14. Adenosine 3',5'-monophosphate response to parathyroid hormone: familial hypocalciuric hypercalcemia versus typical primary hyperparathyroidism.
Marx SJ; Spiegel AM; Sharp ME; Brown EM; Gardner DG; Downs RW; Attie MF; Stock JL
J Clin Endocrinol Metab; 1980 Mar; 50(3):546-8. PubMed ID: 6244324
[TBL] [Abstract][Full Text] [Related]
15. Effect of intravenous glucagon on the urinary excretion of adenosine 3',5'-monophosphate in man and in rats. Evidence for activation of renal adenylate cyclase and formation of nephrogenous cAMP.
Rubinger D; Wald H; Friedlaender MM; Silver J; Popovtzer MM
Miner Electrolyte Metab; 1988; 14(4):211-20. PubMed ID: 2850459
[TBL] [Abstract][Full Text] [Related]
16. Renal effects of native parathyroid hormone and synthetic biologically active fragments in pseudohypoparathyroidism and hypoparathyroidism.
Neer RM; Tregear GW; Potts JT
J Clin Endocrinol Metab; 1977 Feb; 44(2):420-3. PubMed ID: 190258
[TBL] [Abstract][Full Text] [Related]
17. A 6-hour human parathyroid hormone (1-34) infusion protocol: studies in normal and hypoparathyroid subjects.
McElduff A; Lissner D; Wilkinson M; Cornish C; Posen S
Calcif Tissue Int; 1987 Nov; 41(5):267-73. PubMed ID: 2825934
[TBL] [Abstract][Full Text] [Related]
18. Abnormal responsiveness of nephrogenous cyclic AMP excretion following intravenously administered calcium in normocalcaemic squamous cell cancer patients.
Naafs MA; Hackeng WH; Koorevaar G; Silberbusch J
Bone Miner; 1988 Jul; 4(3):289-98. PubMed ID: 2847840
[TBL] [Abstract][Full Text] [Related]
19. Effect of chlorpropamide on renal response to parathyroid hormone in normal subjects and in patients with hypoparathyroidism and pseudohypoparathyroidism.
Coulson R; Moses AM
J Pharmacol Exp Ther; 1975 Sep; 194(3):603-13. PubMed ID: 169346
[TBL] [Abstract][Full Text] [Related]
20. Pseudohypoparathyroidism showing positive phosphaturic and negative cyclic AMP excretion response to parathyroid hormone.
Higashi K; Honda K; Morita M; Umeda T; Shimada T; Kimura K; Shido T; Arita I; Sato T
Endocrinol Jpn; 1989 Aug; 36(4):465-9. PubMed ID: 2555146
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
